Search

Your search keyword '"Perrotta, Fabio"' showing total 6 results
Start Over Author "Perrotta, Fabio" Journal clinical rheumatology
6 results on '"Perrotta, Fabio"'

4. Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate

Author

Costa, Luisa, primary, Lubrano, Ennio, additional, Ramonda, Roberta, additional, Chimenti, Maria Sole, additional, Vezzù, Maristella, additional, Perrotta, Fabio M., additional, Del Puente, Antonio, additional, Peluso, Rosario, additional, Bottiglieri, Paolo, additional, Lorenzin, Mariagrazia, additional, Sunzini, Flavia, additional, Darda, Md Abud, additional, Fiocco, Ugo, additional, Perricone, Roberto, additional, Punzi, Leonardo, additional, Scarpa, Raffaele, additional, and Caso, Francesco, additional

Published
2017
Full Text
View/download PDF

5. Role of comorbidities in spondyloarthritis including psoriatic arthritis.

Author

Scriffignano, Silvia, Perrotta, Fabio Massimo, De Socio, Antonia, and Lubrano, Ennio

Subjects
*PSORIATIC arthritis, *HEALTH resorts, *QUALITY of life
Abstract

Spondyloartrhitis (SpA) are a group of diseases characterized by inflammation at articular and entheseal sites. Moreover, patients with SpA suffer from impaired articular function and reduced quality of life. Beyond the articular involvement, SpA and in particular psoriatic arthritis (PsA) are associated with extra-articular manifestations and comorbidities that might increase the burden of the disease. The aim of this article was to review the available evidences on the presence of comorbidities in SpA, including PsA, focusing the attention on the cardiovascular, metabolic aspects, as well as other comorbidities, and their possible management in an integrated manner. Comorbidities in SpA should be carefully evaluated because of their important impact. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

6. Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate

Author

Leonardo Punzi, Roberto Perricone, Maria Sole Chimenti, Rosario Peluso, Flavia Sunzini, Mariagrazia Lorenzin, Abud Darda, Luisa Costa, Ugo Fiocco, Antonio Del Puente, Fabio Massimo Perrotta, Francesco Caso, Ennio Lubrano, M. Vezzù, Raffaele Scarpa, Paolo Bottiglieri, Roberta Ramonda, Costa, Luisa, Lubrano, Ennio, Ramonda, Roberta, Chimenti, Maria Sole, Vezzù, Maristella, Perrotta, Fabio M, DEL PUENTE, Antonio, Peluso, Rosario, Bottiglieri, Paolo, Lorenzin, Mariagrazia, Sunzini, Flavia, Darda, Md Abud, Fiocco, Ugo, Perricone, Roberto, Punzi, Leonardo, Scarpa, Raffaele, and Caso, Francesco

Subjects
Male, MDA, Inflammatory arthritis, Psoriatic, Severity of Illness Index, Etanercept, 0302 clinical medicine, 030212 general & internal medicine, TNF-α blockers, Elderly PsA patient, Remission Induction, General Medicine, Middle Aged, Treatment Outcome, Italy, Antirheumatic Agents, Elderly PsA patients, Female, medicine.drug, medicine.medical_specialty, Drug discontinuation rate, TNF-α blockers, Rheumatology, 03 medical and health sciences, Psoriatic arthritis, Internal medicine, medicine, Adalimumab, Humans, Adverse effect, Aged, 030203 arthritis & rheumatology, Biological Products, Tumor Necrosis Factor-alpha, business.industry, Arthritis, Arthritis, Psoriatic, medicine.disease, Infliximab, Golimumab, Surgery, Settore MED/16 - Reumatologia, Regimen, business
Abstract

Psoriatic arthritis (PsA) is an inflammatory arthropathy, associated with skin and/or nail psoriasis. Real world data on efficacy and safety of TNF-α blockers in the elderly with PsA are lacking. The aim of this study was to evaluate the effectiveness, through the achievement of minimal disease activity (MDA), drug discontinuation rate, and safety in elderly patients with PsA on TNF-α blockers. A multicenter, observational study was carried out in four Italian centers. The assessment of disease activity and safety were performed at the start of anti-TNF-α (T0), at 6 months (T6) and at 12 months (T12). A total of 145 PsA patients were included in the study. At baseline 68 (46.9%) patients were on etanercept, 60 (41.3%) on adalimumab, 11 (7.6%) on golimumab, and 6 (4.1%) on infliximab. All the variables concerning PsA activity showed a statistically significant improvement when comparing T6 and T12 with T0. After 6 and 12 months of therapy, respectively, 31 (22.6%) and 71 (51.8%) patients achieved MDA (p

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results